About Oral PrEP

Advocacy starts with information. Learn more about the evidence that shows oral PrEP works.

Daily oral PrEP works if you take it. That’s the bottom line about this prevention strategy, rolling out with tenofovir-based drugs in countries and communities worldwide. At the same time, other forms of ARV-based primary prevention, including the dapivirine vaginal ring and long-acting injectable PrEP using the antiretroviral cabotegrevir are on the horizon as possible additions to the PrEP toolbox.

Explore this section to learn about:

PrEP research today spans implementation research on delivering daily oral tenofovir-based PrEP and clinical trials of new agents.

Clinical Trials Evidence — The 2012 US FDA decision and WHO guidance on PrEP demonstration projects were based on data from randomized controlled trials of tenofovir-based oral PrEP. Additional randomized trials since then have added to this evidence base.

Open-Label and Demonstration Project Evidence — Concluded and ongoing pilot projects, demonstration projects and open-label studies offer insight into how PrEP works in the “real world”—outside of the controlled environment of a clinical trial.

Ongoing Research — There are a range of ARV-based prevention options being evaluated today. These include long-acting injectable ARVs for HIV-negative people, a vaginal ring containing the ARV dapivirine, additional oral PrEP options and more.

PrEP Watch was created and is maintained by AVAC, a non-profit organization based in New York that uses education, policy analysis, advocacy and a network of global collaborations to accelerate the ethical development and global delivery of new and emerging HIV prevention options as part of a comprehensive response to the HIV/AIDS pandemic. AVAC receives no money from pharmaceutical companies, including Gilead Sciences. If you have a comment or suggestion regarding the content of this site, click here to contact us. Read our privacy policy.